Integra LifeSciences(IART) - 2022 Q4 - Earnings Call Presentation

Neurosurgery market recovery offset by CereLink recall and supply challenges Revenues Q4'22 Q4'21 Growth 1 Q4'21 reported revenue includes TWC 2Q4'22 excludes $0.5M of acquired SIA revenues and ($1.1M) in foreign exchange; 3Percentages based on organic revenue, Commentary represents organic performance, Comparisons are to prior year Adj. Gross Profit Adj. EBITDA Adj. EPS Adj. Gross Profit Adj. EBITDA Adj. EPS 0 0.2 0.4 0.6 0.8 1 1.2 $1,043.5$1,046.4 -20 -15 -10 -5 0 5 10 15 20 FY'21 FY'22 325 335 345 355 3 ...